[Biochemical assessment of the effects of coronary thrombolysis by serum cardiac myosin light chain levels].
To establish the method of biochemical assessment of effects of intracoronary thrombolysis after acute myocardial infarction (MI), the relationships between plasma creatine kinase (CK) or serum cardiac myosin light chain (LC) I levels and changes in left ventricular (LV) wall motion were evaluated. Twenty-seven cases with acute MI without previous infarction were included in this study. Intracoronary thrombolysis was successful within seven hours after onset of MI in 13 patients (reperfusion group), and 14 patients were treated in a conventional manner (control group). Peak levels of CK reached earlier in the reperfusion group (11.3 +/- 2.9 hours) than in the control group (20.9 +/- 5.3 hours). The peak appearance time of CK in the reperfusion group was significantly related to the time between the onset of MI and achievement of coronary reperfusion (r = 0.76). The relationship between total CK release and LV ejection fraction determined by cineangiography one month after onset was not good (r = -0.42). Peak levels of CK were not related to LV ejection fraction. Peak levels of LC appeared about four days after onset in both groups. Peak levels of LC were closely related to LV ejection fraction (r = -0.72). Twenty-four-hour and four-day levels of LC were also related to LV ejection fraction (r = -0.62 and -0.73, respectively). Peak levels of LC were related to asynergic area determined by biplane cineangiography.(ABSTRACT TRUNCATED AT 250 WORDS)
D000368:Aged; D003327:Coronary Disease / Q000628:therapy*; D003328:Coronary Thrombosis / Q000628:therapy*; D003402:Creatine Kinase / Q000097:blood; D005069:Evaluation Studies as Topic; D006801:Humans; D008875:Middle Aged; D009200:Myocardial Contraction; D009203:Myocardial Infarction / Q000628:therapy*; D015879:Myosin Subfragments; D009218:Myosins / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood*; D010477:Perfusion; D013318:Stroke Volume; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage
D015879:Myosin Subfragments; D010446:Peptide Fragments; D003402:Creatine Kinase; D014568:Urokinase-Type Plasminogen Activator; D009218:Myosins